SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Ionis Pharmaceuticals (IONS)
An SI Board Since May 1996
Posts SubjectMarks Bans Symbol
4676 121 0 IONS
Emcee:  Keith Fauci Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
4376Webcast Alert: Isis Pharmaceuticals Announces Financial Results and Highlights fbob zagorin-3/3/2008
4375hah! see if you can top this;) Oral Delivery (ISIS 104838 targets TNF-alpha.) bob zagorin-2/26/2008
4374There is some DGAT competition. Abbott is definitely a competitor: >> J tuck-2/26/2008
4373I'll see you that abstract and raise you . . . >>Biochim Biophtuck-2/26/2008
4372More on NASH (repost from IV) URL link found on Isis website www3.interscience.bob zagorin-2/26/2008
4371Antisense Therapeutics Ltd Licenses ATL1102 to Teva Pharmaceutical Industries Ltbob zagorin-2/20/2008
4370wachovia p3 (repost from IV) "...WACHOVIA ANALYSIS RE:T500 DEAL-WORTH $4-$bob zagorin-2/19/2008
4369more wachovia on isis p2 (repost from IV) "...Wachovia comments re: NMR stbob zagorin-2/19/2008
4368more from wachovia p1. repost from IV "...ISIS: Increasing Ests.-- 2008 Offbob zagorin-2/19/2008
4367ISIS P3 trial of 301012 (mipomersen) has begun. FDA listing with details: www1bob zagorin-2/17/2008
4366>>OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint tuck-2/15/2008
4365new report shows isis 4th in all of biotech for IP estate.. bioresearchonline.cbob zagorin-2/14/2008
4364fidelity now owns 15% of isis! up from around 10% last filing.. xml.10kwizard.cbob zagorin-2/14/2008
4363ASCO: files.shareholder.com@%20ASCO-GU.pdfbob zagorin-2/14/2008
4362federated reports 14.64% stake in isis.. xml.10kwizard.combob zagorin-2/13/2008
4361excerpts from GENZ report today... "...-- Non-GAAP research and developmenbob zagorin-2/13/2008
4360Abstract of new article linked on Isis's 'Publications' web page: cbob zagorin-2/13/2008
4359Isis Announces Approximately $2.8 Million in Government Grants and Contracts Awabob zagorin-2/12/2008
4358 Web address: sciencedaily.com 080207140851.htm How One Protein Binds To bob zagorin-2/11/2008
4357Regulus Therapeutics Appoints Peter S. Linsley, Ph.D. as Chief Scientific Officebob zagorin-2/11/2008
4356another little revenue stream for isis.. Sydney, Feb 11, 2008 (RWE via COMTEX) bob zagorin-2/10/2008
4355investors.com HEALTH & MEDICINE Analyst Sees Plenty Of Opportunity In Biotecbob zagorin-2/9/2008
4354ISIS + ALNYLAM= Regulus- UK Patent News 8-Feb-08 04:31 pm genengnews.cobob zagorin-2/8/2008
4353Bob Thanks for your forthright opinion. Like you I have trimmed as I bought abMJ-2/8/2008
4352jmho. there is some disenchantment with the ibis deal thinking that isis sold tobob zagorin-2/8/2008
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News